Table 4.
Clinical data and biochemical results for AKI COVID-19 patients.
| AKI patients N = 15 |
KDIGO Stage 1 |
KDIGO Stage 2 |
KDIGO Stage 3 |
p |
|---|---|---|---|---|
| N, % | 10 (66.7) | 2 (13.3) | 3 (20.0) | < 0.001 |
| Age (years) | 59.8 (32.1) | 84.3 (6.0) | 71.3 (17.6) | 0.002 |
| Male (n, %) | 7/10 (70.0) | 2/2 (100) | 2/3 (66.7) | 0.009 |
| DM (n, %) | 2/10 (20.0) | 2/2 (100) | 0/3 (0) | 0.002 |
| HT (n, %) | 7/10 (70.0) | 2/2 (100) | 2/3 (66.7) | 0.009 |
| Obesity (n, %) | 4/10 (40.0) | 0/2 (0) | 1/3 (33.4) | 0.001 |
| CKD (n, %) | 2/10 (20.0) | 2/2 (100) | 0/3 (0) | 0.002 |
| HF (n, %) | 0/10 (0) | 0/2 (0) | 0/3 (0) | 1.000 |
| Episode time (days) | 4 (5.5) | 2 (0.5) | 5 (8.6) | 0.006 |
| ICU (n, %) | 2/10 (20.0) | 0/2 (0) | 2/3 (66.7) | 0.001 |
| ACET (n, %) | 2/10 (20.0) | 1/2 (50.0) | 1/3 (33.4) | 0.002 |
| RRT (n, %) | 1/10 (10.0) | 0/2 (0) | 1/3 (33.4) | 0.009 |
| TI (n, %) | 2/10 (20.0) | 0/2 (0) | 2/3 (66.7) | 0.001 |
| Non-survivors (n, %) | 2/10 (20.0) | 0/2 (0) | 3/3 (100) | < 0.001 |
| Creatinine baseline (mg/dL) | 1.22 (0.56) | 3.10 (0.17) | 0.91 (1.04) | 0.001 |
| Creatinine peak (mg/dL) | 1.83 (0.68) | 3.10 (0.17) | 3.24 (0.92) | 0.002 |
| eGFR (mL/min per 1.73m2) | 40.5 (16.0) | 17.5 (0.5) | 17.0 (5.0) | 0.010 |
Quantitative variables were described by mean ± standard deviation or median (IQR); AKI, Acute Kidney Injury; DM, Diabetes; HT, Hypertension; CKD, Chronic kidney disease; HF, Heart failure; ICU, Intensive Care Unit; RRT, Renal replacement therapy; TI, Tracheal intubation; ACET, Angiotensin convertase enzyme inhibitors therapy; eGFR, Estimated glomerular filtration rate; KDIGO, Kidney Disease Improving Global Outcomes.